Targeting F13 from monkeypox virus and variola virus by tecovirimat: Molecular simulation analysis
- PMID: 35810941
- DOI: 10.1016/j.jinf.2022.07.001
Targeting F13 from monkeypox virus and variola virus by tecovirimat: Molecular simulation analysis
Conflict of interest statement
Declaration of Competing Interest The authors declare that there are no conflicts of interest.
Comment in
-
CRISPR-Cas12a-based detection of monkeypox virus.J Infect. 2022 Dec;85(6):702-769. doi: 10.1016/j.jinf.2022.08.043. Epub 2022 Sep 7. J Infect. 2022. PMID: 36084670 Free PMC article. No abstract available.
-
Clinical experience with use of oral Tecovirimat or Intravenous Cidofovir for the treatment of Monkeypox in an Italian reference hospital.J Infect. 2023 Jan;86(1):66-117. doi: 10.1016/j.jinf.2022.11.001. Epub 2022 Nov 5. J Infect. 2023. PMID: 36347428 Free PMC article. No abstract available.
Comment on
-
Monkeypox: A new threat at our doorstep!J Infect. 2022 Aug;85(2):e47-e48. doi: 10.1016/j.jinf.2022.05.027. Epub 2022 May 29. J Infect. 2022. PMID: 35649489 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
